Spero Therapeutics, Inc. has announced a significant change in its board of directors, with the resignation of Dr. Patrick Vink and the appointment of Dr. William Ho as his successor. This leadership transition is crucial as it may influence the company's strategic direction and operations in the competitive pharmaceutical preparations industry.
On November 9, 2026, Dr. Vink notified the board of his decision to resign from his position as a Class II director, effective November 10, 2026. He also stepped down from his roles as Chair of the Nominating and Corporate Governance Committee and member of the Compensation Committee. The company expressed gratitude for Dr. Vink's 11 years of service.
Dr. Ho, appointed to fill the vacancy created by Dr. Vink's resignation, brings over 20 years of clinical development experience across various therapeutic areas, including oncology and immunology. His previous roles include Chief Medical Officer at RAPT Therapeutics, where he played a pivotal role in the company's successful acquisition by GSK.
Dr. Ho's appointment is expected to enhance Spero Therapeutics' capabilities in clinical development and innovation. He will serve as a Class II director until a successor is duly elected or appointed. Additionally, he has been appointed to the Development Committee of the Board.
In connection with his new role, Dr. Ho will receive an annual cash retainer of $40,000 for his board service and an additional $5,000 for his role on the Development Committee. He has also been granted an option to purchase 100,000 shares of the company's common stock, vesting over one year.
These leadership changes come at a time when Spero Therapeutics is navigating a competitive landscape in the pharmaceutical preparations sector. The company is expected to leverage Dr. Ho's extensive experience to enhance its strategic initiatives and clinical programs.
Looking ahead, the company has not disclosed any specific next steps following these appointments. However, stakeholders will be keen to see how this transition impacts Spero Therapeutics' direction and performance in the pharmaceutical market.
For further details, the full filing can be accessed through the SEC under accession number 0001193125-26-455789.
Read Next
Sven-Olof Lindblad sells shares in Lindblad Expeditions
Zeo Energy CEO Timothy Bridgewater Acquires 107,955 Shares
Manthripragada Vijay Acquires Additional Shares in Onterris
Laws James Acquires Shares in Onterris, Inc. via RSUs
Eightco Holdings CEO Acquires 100,000 Shares of Stock
Eightco CFO Vroman Acquires 15,000 Shares in Stock Transaction





